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ORIGINAL INVESTIGATION
The impact of cardiovascular 
co-morbidities and duration of diabetes on the 
association between microvascular function 
and glycaemic control
F. Casanova1, D. D. Adingupu1, F. Adams2, K. M. Gooding1, H. C. Looker2, K. Aizawa1, F. Dove2, S. Elyas1, 
J. J. F. Belch2, P. E. Gates1, R. C. Littleford2, M. Gilchrist1, H. M. Colhoun2, A. C. Shore1, F. Khan2* and W. D. Strain1* 
Abstract 
Background: Good glycaemic control in type 2 diabetes (T2DM) protects the microcirculation. Current guidelines 
suggest glycaemic targets be relaxed in advanced diabetes. We explored whether disease duration or pre-existing 
macrovascular complications attenuated the association between hyperglycaemia and microvascular function.
Methods: 743 participants with T2DM (n = 222), cardiovascular disease (CVD = 183), both (n = 177) or neither (con-
trols = 161) from two centres in the UK, underwent standard clinical measures and endothelial dependent (ACh) and 
independent (SNP) microvascular function assessment using laser Doppler imaging.
Results: People with T2DM and CVD had attenuated ACh and SNP responses compared to controls. This was additive 
in those with both (ANOVA p < 0.001). In regression models, cardiovascular risk factors accounted for attenuated ACh 
and SNP responses in CVD, whereas  HbA1c accounted for the effects of T2DM.  HbA1c was associated with ACh and 
SNP response after adjustment for cardiovascular risk factors (adjusted standardised beta (β) −0.096, p = <0.008 and 
−0.135, p < 0.001, respectively). Pre-existing CVD did not modify this association (β −0.099; p = 0.006 and −0.138; 
p < 0.001, respectively). Duration of diabetes accounted for the association between  HbA1c and ACh (β −0.043; 
p = 0.3), but not between  HbA1c and SNP (β −0.105; p = 0.02).
Conclusions: In those with T2DM and CVD, good glycaemic control is still associated with better microvascular 
function, whereas in those with prolonged disease this association is lost. This suggests duration of diabetes may be a 
better surrogate for “advanced disease” than concomitant CVD, although this requires prospective validation.
Keywords: Diabetes, Cardiovascular disease, Microcirculation, Glycaemic legacy
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Whereas cardiovascular disease (CVD) is responsible for 
the majority of mortality in people with type 2 diabetes 
mellitus (T2DM), the microvascular complications, such 
as retinopathy and nephropathy, have the greatest impact 
on patient’s quality of life [1] and the economic cost of 
patients’ management [2]. Good glycaemic control has 
been demonstrated to halt, or at least slow, progression 
of these microvascular complications in early diabetes 
(within 12  months of diagnosis) in otherwise healthy 
people with diabetes [3, 4]. Recent trials, however, have 
suggested that this benefit is attenuated, or even absent 
in those with long-established complex T2DM (>5 years) 
[5–7]. Indeed, the ACCORD trial failed to show any 
benefits on microvascular complications from inten-
sive glycaemic control and a paradoxical 22% increase in 
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cardiovascular events, thought to be due to the adverse 
metabolic impact of hypoglycaemia and weight gain on a 
background of prolonged adverse glycaemic legacy. As a 
result, national and international guidelines now advocate 
relaxation of targets for glycaemic control in “advanced 
T2DM” [8] in order to reduce the potential side effects 
of therapy in a setting where the therapeutic poten-
tial of glycaemic control is limited. The term “advanced 
T2DM”, however, is ambiguous and open to interpreta-
tion. It is often defined interchangeably as a prolonged 
duration of diabetes or by the presence of complications 
such as CVD or renal disease. As most clinical trials have 
recruited patients based on a composite of these charac-
teristics, it is difficult to determine which should play the 
dominant role in defining targets for glycaemic control. 
Recently, cardiovascular outcome trials such as LEADER 
[9] and Sustain-6 [10] have demonstrated a differential 
benefit on major adverse cardiac events (MACE) in those 
with pre-existing CVD compared to those at high risk 
of a cardiovascular event. In these studies, participants 
who were recruited without experiencing a previous 
event failed to gain any additional benefit from the GLP-1 
based therapy, whereas treatment incurred a risk reduc-
tion in those who had experienced previous CV events. 
This raises doubts over the equal weight placed on pre-
existing CVD/co-morbidities and duration of disease 
when it comes to target setting for glycaemic control.
When setting targets for glycaemic control in people 
with T2DM, physicians are often faced with individuals 
with new onset T2DM but pre-existing CVD, or con-
versely a long duration of T2DM in the absence of any 
macrovascular complications. These patients would 
not have been adequately considered in previous trials; 
in UKPDS, for example, only 7.5% of patients had pre-
existing cardiovascular disease [3]. Given the principle 
role of good glycaemic control is to reduce progression 
of microvascular complications, physicians are left with 
the conundrum of how much weight to give each of these 
“target modifiers” (namely duration of T2DM and pre-
existing CVD/co-morbidities) in establishing their thera-
peutic target.
In the absence of specific interventional studies, there-
fore, we rely on cross-sectional, “association” studies to 
inform and guide strategies for individualisation of treat-
ment goals. Only a very small number of studies have 
attempted to address the effects of CVD risk, comorbidi-
ties and duration of T2DM on the association between 
glycaemic control and microvascular function. These 
have provided conflicting results, possibly due to the 
small number of patients involved in these studies [11–
14]. As such it is unclear whether there is a disjunction 
between glycaemic control and progression of micro-
vascular disease in advanced T2DM and whether this 
is a function of concomitant vascular disease in larger 
conduit vessels, shared risk factors with atherosclerotic 
disease, or simply pre-existing prolonged exposure to 
hyperglycaemia.
Structural changes in retinal vessel are associated with 
increased risk of CVD with some studies suggesting this 
might be true in women but not in men [15]. In diabetes 
retinal changes are believed to reflect systemic changes 
and have been suggested as a potential biomarker for 
microvascular complications [16]. These studies tend 
to address the relationship between structural changes 
within the microcirculation and DM and/or CVD 
with little information about functional changes to the 
microvessels.
Skin microcirculation is an established model to inves-
tigate systemic micro-vessel function [17, 18], further it 
has been independently associated with symptomatic 
coronary artery disease [19] and can be specifically inter-
rogated to measure endothelium-dependent and -inde-
pendent responses [20], thus providing information 
on subclinical changes in vessel function. In the present 
study, we explored the association between glycaemic 
control and microvascular function in patients with and 
without established T2DM and CVD.
We hypothesised that the diminished microvascular 
function previously described in those with T2DM will 
be a function of glycaemic control, whereas the impaired 
microvascular function in those with CVD will be a func-
tion of their conventional CVD risk factors. Further, we 
aimed to explore whether duration of T2DM, as a meas-
ure of adverse glycaemic legacy, or the presence of pre-
existing CVD/co-morbidities, attenuated the association 
between glycaemic control and microvascular function.
Methods
Ethics approval
This study conformed to the Declaration of Helsinki and 
was approved by the National Research Ethics Service 
Southwest (09/H0202/49 and 10/H0206/67) and the East 
of Scotland Research Ethics Service (Tayside Commit-
tee; 10/S1402/44). All participants gave informed written 
consent.
Study population
Participants were part of the “surrogate markers for 
micro- and macro-vascular hard endpoints for innova-
tive diabetes tools” (SUMMIT) program (IMI Grant 
Number 115006; http://www.imi-summit.eu) and were 
recruited from EXTEND (Exeter 10000, NIHR Exeter 
Clinical Research Facility), the Royal Devon and Exeter 
NHS clinical service, the UK type 2 diabetes case–control 
collection Wellcome study and via the Scottish primary 
care research network, the Scottish diabetes research 
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network research network, secondary care diabetes clin-
ics and through advertising such as posters and leaflets. 
Participants were adult men and women, enhanced with 
individuals with T2DM and/or proven CVD. T2DM was 
diagnosed by the patients’ physician after two consecu-
tive  HbA1c above 48  mmol/mol. CVD was defined as 
previously described [21] and included a medical history 
of myocardial infarction, percutaneous coronary inter-
vention (PCI), coronary arterial bypass graft (CABG), 
unstable angina and specialist diagnosed cerebrovascular 
event from Stroke and Cardiology units and clinics at the 
Royal Devon and Exeter Hospital and Ninewells Hospi-
tal, Dundee. CKD was defined as an estimated glomer-
ular filtration rate of <60mL/min (estimated using the 
MDRD formula).
Screening
Screening assessment included a medical history inter-
view, including pharmacotherapy, electrocardiogram 
and anthropometry measures. Measures to a standard 
protocol included height, weight and waist-to-hip ratio 
[22]. Blood pressure was measured as the mean of three 
supine brachial measurements using an automated blood 
pressure device (Omron M6, Omron Healthcare Europe 
B.V. Hoofddorp, The Netherlands). Ankle-brachial index 
was calculated from the highest value of the ankle read-
ing for posterior tibia or dorsalis pedis pressure, and the 
highest reading from the brachial artery (right or left). 
Measurements were taken using a Doppler probe (Dop-
pler D900, Huntleigh Health Care, Cardiff, UK) and 
sphygmomanometer.
Twelve-hour-fasting blood samples were collected 
from all participants for the measurement of glucose 
and lipid concentrations either on the day of the study or 
within a week of the study day when not possible (Exeter 
and Dundee Pathology Services, Royal Devon and Exeter 
NHS Foundation Trust, Nantwell NHS trust), in accord-
ance with the UK national quality assessment scheme.
Microvascular assessment
All participants attended the clinical research facilities 
having refrained from food or drink (except water) at 
least 2  h before the visit, and avoided smoking, drink-
ing tea or coffee, alcohol and strenuous exercise on the 
study day. Medications were omitted on the morning of 
the study, wherever possible. All studies were performed 
in temperature-controlled laboratories (23 ± 1  °C), with 
the participants lying in the supine position following an 
acclimatisation period of at least 20 min. The volar aspect 
of the right forearm was wiped gently with alcohol (Kler-
cide 70/30) and then sterile water. Perspex direct elec-
trode chambers [30 mm total diameter × 3 mm height, 
inner (drug) chamber 10  mm diameter] were attached 
using a double-sided adhesive ring, avoiding visible 
veins, freckles and hair. Chambers were filled with solu-
tions under test; ACh (1% Miochol-E dissolved in man-
nitol, Novartis, Camberly, UK) and SNP (0.25%) (25 mg/
mL Nitropress dissolved in 0.45% saline, Hospira, Lake 
Forest, USA). A glass cover slip was placed on the drug 
chamber to prevent reflection artefacts from the solution 
in the chamber when recording with the laser Doppler 
perfusion imager. An indifferent electrode was attached 
to the volar aspect of the participant’s wrist and con-
nected to the chamber terminal to complete the circuit.
Identical solid-state laser Doppler imagers (LDI, Moor 
Instruments MODEL LDI2) were used in each centre 
(one in Exeter, one in Dundee) to measure skin micro-
vascular perfusion, with the head of the LDI positioned 
50  cm above the centre of the Perspex chamber. Skin 
microvascular perfusion is measured from the laser 
Doppler flux which is proportional to the average speed 
of red blood cells and their concentration. The LDI was 
set to scan a region of 4.8  cm2. The LDI was interfaced 
with a computer equipped with moorLDI windows PC 
dedicated software (research version 5.3). A battery-
powered iontophoresis controller (MIC 1; Moor Instru-
ments, Axminster, UK) was used to provide the current 
for iontophoresis.
ACh was delivered using five pulses (100  μA each) of 
anodal current with a 60  s interval between each dose 
(total charge 12  mC). Twenty-three consecutive 20  s 
recordings were made of forearm skin red blood cell 
flux (Additional file 1: Figure S1). There was no interval 
between these recordings.
SNP was delivered by cathodal current. A single pulse 
of 200 micro amps was introduced for 60 s (total charge 
10  mC). Forearm skin red blood cell flux was again 
recorded in 20 s units, 21 times with no interval between 
scans.
Median perfusion response was calculated for each 
image obtained by the LDI using the total area to which 
the drug was applied. Skin microvascular perfusion was 
expressed in arbitrary units (arb.) and the peak response 
was measured and defined as the highest skin perfusion 
response reached during iontophoresis delivery of ACh 
and SNP.
Endo‑PAT: endothelial function
In a subgroup of 458 participants from the Exeter cohort 
(controls  =  107, T2DM no CVD  =  117, T2DM with 
CVD  =  105, CVD only  =  129) we assessed arterial 
endothelial function using Endo-PAT 2000 (Itamar Medi-
cal, Israel) measuring changes in the digital pulse wave-
form (PAT, peripheral Arterial Tone) by plethysmography 
following a 5 min occlusion. The baseline data were col-
lected for a period of 10  min, a supra-systolic blood 
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pressure cuff was then inflated on the upper arm of the 
non-dominant arm for exactly 5  min before instantane-
ous release and recording for a further 10 min.
The relative hyperaemia index (RHI) which reflects 
endothelial function is automatically calculated accord-
ing to the following formula by the Endo-PAT2000 
software.
where, A is the mean amplitude of oscillation on test arm 
from 1.5 to 2.5 min post occlusion; B is the mean ampli-
tude of oscillation on test arm during baseline; C is the 
mean amplitude of oscillation on control arm from 1.5 to 
2.5 min post occlusion; D is the mean amplitude of oscil-
lation on control arm during baseline.
Statistical analysis
Where possible analysis was performed on continuous 
data to maximise power. Skewed variables were appropri-
ately transformed, and geometric means (inter-quartile 
range are presented). Statistical significance for categori-
cal variables was calculated using the Chi squared test 
and the ANOVA for continuous variables, with individual 
group differences assessed by Student’s t test. Analysis of 
co-variance was employed to determine explanations for 
differences between those with and without T2DM and 
CVD in key variables, with tests for interaction.
A result was deemed significant if p  ≤  0.05 for the 
ANOVA. In cases were comparisons are performed 
between four groups (i.e. six comparisons), a p value of 
<0.008 is regarded as significant. In the assessment of the 
optimal model which accounts for association between 
glycaemia and microvascular disease, where three mod-
els are compared, a p value of <0.017 is regarded as sig-
nificant. Where multiple comparisons have occurred p 
values are reported in full for information purposes only. 
All analysis were performed using STATA (version 14.1, 
StataCorp, Texas USA).
In attempting to explain differences encountered 
between those with and without diabetes and/or CVD, 
multiple regression modelling was performed taking into 
account putative confounders or modifiers of the rela-
tionship. Confounding factors considered were age and 
sex, and mechanistic factors considered were obesity 
(weight, BMI, waist circumference, hip circumference 
and waist: hip ratio), blood pressure indices (brachial 
systolic, ankle systolic, brachial diastolic, mean arterial 
pressure, 24  h mean ambulatory blood pressure, day-
time mean systolic blood pressure, night-time mean 
systolic blood pressure and day: night systolic blood 
pressure ratio) lipid profile (total cholesterol, HDL cho-
lesterol, cholesterol: HDL ratio and fasting triglyceride) 
and smoking status. When considering the contribution 
RHI =
(
A
/
B
)/(
C
/
D
)
× Baseline correction (BC) factor
of glycaemia, fasting glucose and  HbA1c were considered. 
A single variable from each of these groups (body habi-
tus, blood pressure, lipids, smoking and glycaemia) was 
included based on the greatest increase in the amount of 
variance explained by the model (R-squared value). The 
impact of adding additional variables in accounting for 
the variance of the model was tested by the likelihood 
ratio statistic (LRS). Polypharmacy (either as drug class 
or total tablet burden) were considered, however did not 
contribute to the model.
Results
Clinical characteristics
Those with T2DM had a higher  HbA1c and BMI. Those 
with T2DM or CVD were more likely to be treated with 
anti-hypertensive and statins compared with the healthy 
controls (Table 1).
Individuals with T2DM were treated with diet only 
(19.5%), oral glucose lowering medications only (58.2%), 
and insulin (with or without oral glucose lowering medi-
cations, 21.0%). Due to local clinical pathways, GLP-1 
based therapy was rarely used (1.3% of people with diabe-
tes). Duration of diabetes ranged from newly diagnosed 
to 39.2 years (mean 9.5 years, median 8 years, IQ range 
4–13). Those with CVD had a longer duration of diabe-
tes, [mean 10.8, median 9.7 (IQ range 4.3–15) years vs. 
mean 8.5 median 7.7 (IQR 4–12) years; p = 0.002]. A his-
tory of myocardial infarction, CABG, PCI or acute cor-
onary syndrome represented 56.8% of those with CVD, 
whilst cerebrovascular problems [ischaemic stroke or 
transient ischaemic attack (TIA)] represented a further 
31.8%. The remaining 11.6% had a history of both cardiac 
and cerebrovascular disease. This distribution was the 
same in those with and without T2DM.
Skin micro vascular response to acetylcholine and sodium 
nitroprusside
The result of the ANOVA test show that endothe-
lium-dependent microvascular response to ACh was 
decreased in patients with either T2DM alone or CVD 
alone compared with those without either condition 
(Fig.  1a). There was an additive effect in patients with 
both T2DM and CVD, such that this group had the poor-
est microvascular function than either those with T2DM 
alone [mean ± SD 414 ± 20 vs. 438 ± 17 arbitrary units 
(arb.) for T2DM  +  CVD vs T2DM alone respectively: 
p  =  0.026] or CVD alone (414  ±  20 vs. 460  ±  20  arb. 
respectively; p < 0.001), and the decline in response was 
numerically similar to the composite effect of each dis-
ease process separately.
The endothelium-independent response to SNP was 
similarly attenuated in patients with both T2DM and 
CVD compared with either T2DM alone (330 ±  23 vs. 
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352  ±  19  arb.; p  =  0.03) or CVD alone (330  ±  23 vs. 
384 ± 20 respectively; p < 0.001) (Fig. 1b). Again, this was 
numerically similar to the additive effect of either alone 
condition alone compared to healthy controls.
Determinants of attenuated microvascular responses 
in those with DM and/or CVD
In keeping with previous reports, in our multiple regres-
sion model conventional CVD risk factors (i.e. age, sex, 
Table 1 Baseline characteristics stratified by group [mean (±SD) except were skewed data in which case geometric mean 
(IQ range) presented]
BMI body mass index, MAP mean arterial pressure, ABPI ankle brachial pressure index, CKD chronic kidney disease, ACR albumin creatinine ratio
a Represents different from control, (p < 0.008 after Bonferonni adjustment for six intergroup comparisons)
b Represents different from CVD alone
c Represents different from diabetes alone
Controls N = 161 CVD only = 183 DM no CVD = 222 DM with CVD = 177 p
Age (years) 64 [58–69] 68 [63–74]a 65 [59–71]b 69 [64–47]a, c <0.001
Gender (M/F) 81/80 136/47 130/92 133/44 <0.001
Height (m) 1.69 (±0.1) 1.69 (±0.1) 1.69 (±0.1) 1.70 (±0.1) 0.428
Weight (kg) 76.0 (±13.7) 80.0 (±12.7) 91.7 (±16.5)a, b 90.2 (±16.6)a, b <0.001
BMI (kg m−2) 26.59 (±4.19) 27.89 (±3.84) 31.93 (±5.59)a, b 30.98 (±4.93)a, b <0.001
Systolic BP (mmHg) 137.5 (±18.2) 136.5 (±17.7) 137.2 (±14.9) 135.4 (±15.4) 0.644
Diastolic BP (mmHg) 79.2 (±8.9) 76.1 (±8.8)a 78.2 (±7.8) 74.1 (±8.6)a, c <0.001
MAP (mmHg) 98.7 (±11.0) 96.2 (±10.6) 97.8 (±8.9) 94.5 (±9.2)a, c <0.001
On anti-hypertensive (%) 50.3 86.3 79.7 94.3 <0.001
ABPI right leg 1.15 (±0.16) 1.11 (±0.19) 1.16 (±0.16) 1.12 (±0.26) 0.018
ABPI Left leg 1.13 (±0.14) 1.11 (±0.16) 1.15 (±0.16) 1.10 (±0.25) 0.042
Total cholesterol (mmol L−1) 5.4 [4.8–6.01] 4 [3.5–4.7]a 4.08 [3.5–4.64]a 3.7 [3.26–4.1]a, b, c <0.001
LDL cholesterol (mmol L−1) 3.18 [2.7–3.8] 1.97 [1.6–2.54]a 1.9 [1.45–2.56]a 1.74 [1.41–2.04]a, b, c <0.001
HDL cholesterol (mmol L−1) 1.54 [1.29–1.9] 1.33 [1.1–1.66]a 1.23 [1.07–1.45]a, b 1.15 [0.93–1.36]a, b 0.035
On statin (%) 14.4 90.0 72.3 89.3 <0.001
CKD STAGE N (%)
 3 8 (4.97%) 25 (13.66%) 21 (9.46%) 40 (22.60%) <0.001
 4 1 (0.62%) 0 (0%) 0 (0%) 4 (2.26%)
 5 0 (0%) 0 (0%) 0 (0%) 0 (0%)
HbA1c (mmol mol−1) 39 [37–41] 40 [38–42] 57 [49–66]a, b 57 [50–69]a, b <0.001
ACR (mg/mmol) 0.59 [0.41–0.93] 0.61 [0.4–1.14] 0.78 [0.5–1.5]a, b 0.93 [0.5–2.15]a, b <0.001
Fig. 1 Endothelial dependent and independent function (mean ± SD) stratified by recruitment group. As multiple comparisons have been made, 
a p < 0.008 should be regarded as statistically significant. a Peak endothelial dependent responses to acetylcholine (ACh); b Peak endothelial inde-
pendent response to sodium nitroprusside (SNP). No DM No CVD: recruited with no evidence of diabetes or overt cardiovascular disease; No DM 
with CVD: recruited with no evidence of diabetes, but pre-existing cardiovascular disease; DM No CVD: recruited with pre-existing diabetes but no 
evidence of cardiovascular disease; DM with CVD: recruited with pre-existing diabetes and cardiovascular disease
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BMI, serum cholesterol and mean arterial pressure) com-
pletely accounted for the effect of CVD on both micro-
vascular endothelium-dependent (adjusted p = 0.1) and 
independent microvascular function (adjusted p  =  0.7; 
Fig. 2). These risk factors could not account for the dif-
ferences between those with and without T2DM (Fig. 3c, 
d). The addition of  HbA1c to the model, however did 
account for the differences between those with and with-
out T2DM (Fig. 3e, f ).
Exploration of the association between glycaemic control 
and microvascular function and the effects of duration 
of T2DM or comorbidities
Both endothelium-dependent and independent micro-
vascular responses were associated with  HbA1c after 
adjustment for age and sex (standardised beta, −0.154, 
p  <  0.001; and −0.171, p  <  0.001 for ACh and SNP, 
respectively) (Table 2). Adjustment for conventional CV 
risk factors did little to attenuate this association (std 
beta −0.093, p = <0.009 and −0.124, p < 0.001, respec-
tively). Polypharmacy, nor any specific drug class did 
not impact the model, however concordant treatment 
algorithms across the two sites had resulted in very little 
heterogeneity in prescribing.
Comorbidities
Inclusion of CVD, CKD or the composite of the two 
made no impact on the association between  HbA1c and 
microvascular function, either numerically or statisti-
cally (adjusted std beta −0.094; p  =  0.008 and −0.125; 
p  <  0.001, for endothelial dependent and independent 
perfusion respectively).
Duration of diabetes
Adjustment for the duration of diabetes entirely 
accounted for the association between  HbA1c and 
endothelium-dependent microvascular function 
(adjusted std beta −0.041; p =  0.3). Endothelium-inde-
pendent function, however, maintained its association 
with  HbA1c, albeit attenuated to borderline significance 
after adjustment for duration of diabetes (adjusted std 
beta −0.092; p  <  0.05). The inclusion of other cardio-
vascular risk factors or comorbidities did not alter this 
association.
Fig. 2 Determinants of attenuated microvascular function in those with cardiovascular disease, irrespective of diabetes, combined (mean ± 95% 
CI). As multiple comparisons have been made, a p < 0.008 should be regarded as statistically significant. a Peak endothelial dependent responses 
to acetyl choline (ACh) in those with and without pre-existing cardiovascular disease adjusted for age and sex (mean ± CI). b Peak endothelial 
independent response to sodium nitroprusside (SNP) in those with and without pre-existing cardiovascular disease adjusted for age and sex. c Peak 
endothelial dependent responses to acetyl choline (ACh) in those with and without pre-existing cardiovascular disease adjusted for age, sex and 
conventional cardiovascular risk factors (body mass index, mean arterial blood pressure, total cholesterol and smoking status). d Peak endothelial 
independent response to sodium nitroprusside (SNP) in those with and without pre-existing cardiovascular disease adjusted for age, sex and 
conventional cardiovascular risk factors (body mass index, mean arterial blood pressure, total cholesterol and smoking status). CVD participants 
recruited with pre-existing cardiovascular disease; No CVD participants recruited with no clinical history of cardiovascular disease
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Endothelial function as measured by ENDOPAT
The RHI, measuring endothelial response to occlusion, was 
significantly different between the four groups (ANOVA 
p  <  0.001: Additional file  1: Figure  S2). After adjustment 
for age, sex and the presence of diabetes, CVD showed a 
trend towards reducing RHI in this subgroup analysis 
(2.47 ± 0.72 for those without CVD vs 2.31 ± 0.75 for those 
with CVD; p = 0.02). Diabetes significantly attenuated RHI 
in the population as a whole (p < 0.001) and when strati-
fied into those with and without CVD, such that in those 
without CVD, the presence of diabetes reduced RHI from 
2.71 ± 0.65 to 2.32 ± 0.68 (p < 0.001) and in those with pre-
existing CVD a similar decline was observed (2.52 ± 0.68 
vs 2.21 ± 0.62 respectively; p = 0.005).
Exploration of the association between glycaemic control 
and ENDOPAT and the effects of duration of T2DM or 
comorbidities
RHI was associated with  HbA1c after adjustment for 
age and sex (standardised beta, −0.172, p  <  0.001). 
Fig. 3 Determinants of attenuated microvascular function in those with diabetes (mean ± 95% CI), irrespective of cardiovascular disease status com-
bined. a Peak endothelial dependent responses to acetylcholine (ACh) in those with and without diabetes adjusted for age and sex. b Peak endothe-
lial independent response to sodium nitroprusside (SNP) in those with and without diabetes adjusted for age and sex. c Peak endothelial dependent 
responses to acetylcholine (ACh) in those with and without diabetes adjusted for age, sex and conventional cardiovascular risk factors (body mass 
index, mean arterial blood pressure, total cholesterol and smoking status). d Peak endothelial independent response to sodium nitroprusside (SNP) 
in those with and without diabetes adjusted for age, sex and conventional cardiovascular risk factors (body mass index, mean arterial blood pressure, 
total cholesterol and smoking status). e Peak endothelial dependent responses to acetylcholine (ACh) in those with and without diabetes adjusted 
for age, sex, conventional cardiovascular risk factors and  HbA1c. f Peak endothelial independent response to sodium nitroprusside (SNP) in those with 
and without diabetes adjusted for age, sex, conventional cardiovascular risk factors and  HbA1c. DM participants recruited with diabetes (including 
those diagnosed during screening); No DM participants recruited with no clinical history of diabetes and no elevated HbA1c at screening
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Inclusion of CVD, CKD or the composite of the two 
made no impact on the association between  HbA1c and 
RHI, either numerically or statistically (adjusted std beta 
−0.171 p  <  0.001). In an analysis reflecting the results 
of the microvascular response to ACh, adjustment for 
the duration of diabetes entirely accounted for the asso-
ciation between ENDOPAT measured endothelial func-
tion and glycaemic control (adjusted std beta −0.009; 
p = 0.902)
Discussion
The results of this study demonstrate for the first time 
that the microvascular dysfunction associated with 
T2DM and CVD are additive. This suggests different 
mechanisms of deterioration in microvascular dysfunc-
tion for the two disease processes. Supporting this find-
ing, we have shown that the differences between those 
with and without CVD are accounted for by traditional 
CVD risk factors, whereas the addition of glycaemic con-
trol to the model is required to account for the microvas-
cular dysfunction due to the presence of T2DM. Further, 
we have demonstrated that this model is essentially 
unaffected by the complexity of disease suggesting links 
between glycaemic control and microvascular function 
are also relevant in complicated diabetes. These find-
ings were mirrored in the only alternative FDA-approved 
measure of endothelial function, suggesting our results 
represent a systemic disposition, rather than localised to 
the skin alone.
If our findings were prospectively validated, one could 
argue that guidelines advocating relaxation of targets 
for glycaemic control in those with multi-morbidity are 
potentially missing an opportunity to slow progression 
of microvascular disease, assuming the targets can be 
achieved without adverse metabolic consequences such 
as hypoglycaemia and weight gain. Duration of T2DM, 
however, accounts for the association between glycaemic 
control and endothelium-dependent microvascular func-
tion. Again, if prospectively reproduced, this would have 
important implications for setting of targets for glycae-
mic control in those with advanced T2DM. Whilst our 
data may suggest that occurrence of CVD and/or CKD 
alone should not cause a relaxing of targets for glycae-
mic control, the benefit from tight glycaemic control on 
the microcirculation may be lost in those with prolonged 
duration of disease. It is important to stress, however, 
that these findings would need to be validated in pro-
spective randomised control trials, individualising treat-
ment targets based on patients’ characteristics. To date, 
however, only one study has even attempted to demon-
strate the feasibility of individualising care [23]. Whilst 
the INTERVAL study demonstrated that achieving indi-
vidualised glycaemic targets was feasible, process of set-
ting such targets themselves was very difficult [24].
It is well established that CVD and T2DM indepen-
dently affect microvascular function [25–27]. Previous 
studies assessing microvascular response to ACh and 
SNP in well-established DM with concomitant acute and 
chronic CVD, however, where inconclusive due to small 
number of patients [11–14]. As a result, they were unable 
to tease out the independent effects of large vessel dis-
ease in those with CVD from the adverse glycaemic leg-
acy associated with a long duration of diabetes.
Although microvascular dysfunction in those with 
CVD is explained by cardiovascular risk factors [25], the 
mechanism through which sustained hyperglycaemia 
causes vascular complications is less clear. Contempora-
neous optimal glycaemic control is not associated with 
improved coronary microvascular response, suggest-
ing that the adverse function may be as a result of gly-
caemic legacy effect [28]. It is generally understood that 
hyperglycaemia acts on endothelial cell function [29] and 
resultant microvascular endothelial dysfunction perpetu-
ates a cycle with a reduction in insulin-mediated glucose 
uptake. Further, the long-term protection granted by 
early good glycaemic control in diabetes (legacy effect) 
remains unclear. The idea of a legacy effect of tight gly-
caemic control was first suggested by the results of 
UKPDS trial [4]. The exact mechanisms of glycaemic 
legacy are not known but epigenetic changes seem to be 
Table 2 Association between  microvascular function 
and HbA1c after adjustment for duration of DM or comor-
bidities (CVD and CKD)
Standardised beta regression coefficient between microvascular function and 
HbA1c after adjustment for potential confounders and putative modifiers. The 
presence of CVD or CKD were given equal weight, the combination of both was 
doubly weighted
DM type 2 diabetes mellitus, CVD clinically confirmed cardiovascular disease, 
CKD chronic kidney disease (defined as an eGFR ≤60 mL/min)
Peak response 
to acetylcholine
Peak response 
to sodium 
nitroprusside
a: After adjustment for age and sex
Standardised 
beta
−0.160 p < 0.001 Standardised 
beta
−0.182 p < 0.001
b: After adjustment for age, sex and conventional CVD risk factors (BMI, 
MAP, total cholesterol and smoking status)
Standardised 
beta
−0.096 p = 0.008 Standardised 
beta
−0.135 p < 0.001
c: After adjustment for age, sex, conventional CVD risk factors and complex 
diabetes (CVD, CKD or the composite)
Standardised 
beta
−0.099 p = 0.006 Standardised 
beta
−0.138 p < 0.001
d: After adjustment for age, sex, conventional CVD risk factors and duration 
of diabetes
Standardised 
beta
−0.043 p = 0.3 Standardised 
beta
−0.105 p = 0.02
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involved [30]. In fact, hyperglycaemia influences gene 
expression both directly, inducing histone acetylation 
and methylation, and indirectly through downstream 
intracellular pathways triggered by oxidative stress which 
also lead to AGE (advanced glycation end-products) for-
mation [29, 31].
Clinicians are often faced with difficulties when 
attempting to interpret recent guidelines for the man-
agement of hyperglycaemia in T2DM, which advocate 
less stringent glycaemic target for a spectrum of patient 
factors including motivation, support networks, dura-
tion of disease and complex diabetes [8]. These chosen 
parameters, however, are based on consensus rather 
than clear evidence. Our work, by demonstrating that 
the association between microvascular function and gly-
caemic control is accounted for by duration of diabetes 
but not complexity of disease, suggests that the current 
guidance requires some prospective validation. Further, 
it also questions guidance to relax glycaemic targets 
in those with newly diagnosed disease but significant 
co-morbidities. The findings clearly need to be verified 
in longer term studies, or by meta-analyses of existing 
data from the landmark clinical trials. ACCORD, VADT 
and ADVANCE-ON [5–7] demonstrated some benefit 
of tight glycaemic control in slowing the microvascu-
lar complications in patients with advanced/complex 
T2DM, although no reduction in cardiovascular events 
or mortality. Further analyses of these data may elucidate 
whether there is a dominant effect of prolonged adverse 
glycaemic legacy or concomitant large vessel disease, on 
microvascular outcomes.
Study limitations
This work has several limitations, most pertinently, the 
cross-sectional nature of our study prevents any causal 
or temporal relationships, as well as any physiopathologi-
cal inferences. Further, it limits the possibility to address 
the question of a threshold effect for duration of T2DM 
and association between  HbA1c and microvascular func-
tion. More studies of a longitudinal nature are needed to 
answer such questions. Secondly, although geographi-
cally distinct, both centres studied a largely white Cau-
casian population so not necessarily translatable to other 
ethnic groups who have a high incidence of T2DM. 
Finally, the use of skin as a marker of systemic microvas-
cular dysfunction has its critics. Previous studies, how-
ever, have shown that the skin microvascular bed can be 
used as a valid marker of more generalised microvascu-
lar function [17, 32]. Further support for this is given in a 
recent systematic review and meta-analysis which dem-
onstrated that several different markers of microvascular 
function, including skin (ACh-mediated responses), eye, 
and kidney, are associated with type 2 DM, suggestive of 
common underlying pathways in different tissues [33]. 
The project is strengthened by the multi-centre design, 
size of this population and the detailed characterisation 
of the participants.
Conclusion
In conclusion, our results indicate that microvascular 
dysfunction is different in CVD and T2DM and therefore 
should be regarded independently. This is important new 
information because microvascular complications, such 
as retinopathy and nephropathy, have the greatest impact 
on a patient’s quality of life. In order to slow or halt pro-
gression of microvascular complications in those with 
T2DM, glycaemic control should be aggressively tar-
geted in early T2DM, even if CVD already exists. Current 
guidelines advocate relaxing glycaemic targets in pro-
longed T2DM, even if the patient is otherwise healthy. 
Our findings are in keeping with these recommenda-
tions, as the association between microvascular function 
and glycaemia appears to be lost, however still require 
prospective validation.
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